Drug Safety

, Volume 29, Issue 12, pp 1133–1152

Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease

  • Raja S Bobba
  • Karen Beattie
  • Bill Parkinson
  • Dinesh Kumbhare
  • Jonathan D. Adachi
Review Article

Abstract

Bisphosphonates are the primary pharmacological agents used for the management of osteoporosis and hypercalcaemia of malignant bone disease. The efficacy of these agents in these two conditions has been demonstrated in many well designed trials published over the past 2 decades. The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used. Despite the fact that bisphosphonates are generally well accepted, their tolerability is dependent on complications which encompass gastrointestinal (GI) and renal toxicity. Other adverse events include osteonecrosis of the jaw, arthralgias, flu-like symptoms and uveitis. Studies have shown that various dosing regimens are able to modulate these rates of toxicity. To maximise tolerability, the direction of future therapy will likely fall into a pattern of decreasing the frequency of administration of bisphosphonates, whether it is oral or intravenous formulations, thus improving patient adherence.

To review the literature on different dosing regimens of various bisphosphonates and their associated tolerability, we searched MEDLINE for articles from 1975 to 2006. Oral bisphosphonates, in particular alendronate and risedronate, have been systematically evaluated with regards to GI toxicity. Overall tolerability with these oral formulations has found GI toxicity to be the primary adverse event of interest. Both alendronate and risedronate have been found to have similar rates of GI toxicity when compared with placebo. Mounting evidence has developed validating the use of intravenous ibandronate and zoledronic acid for the purpose of treating hypercalcaemia secondary to malignancy. Unique to all other bisphosphonates, ibandronate also has an oral form which has a similar GI-toxicity profile to placebo. In addition, no significant differences in renal toxicity have been observed between those receiving intravenous ibandronate compared with placebo. Because of its potency and mode of administration, zoledronic acid has been widely accepted for the treatment of hypercalcaemia secondary to malignancy. However, a decrease in renal function, albeit rare, remains a significant complication of zoledronic acid; therefore, regular renal monitoring is recommended.

References

  1. 1.
    Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71(2): 103–11PubMedCrossRefGoogle Scholar
  2. 2.
    Kherani RB, Papaioannou A, Adachi JD. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review. Drug Saf 2002; 25(11): 781–90PubMedCrossRefGoogle Scholar
  3. 3.
    Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27(3): 165–76PubMedCrossRefGoogle Scholar
  4. 4.
    Cairns AP, Wright SA, Taggart AJ, et al. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 2005; 64(2): 338–9PubMedCrossRefGoogle Scholar
  5. 5.
    Mersfelder T, Armitstead JA, Ivey MF, et al. A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manag Q 1999; 18(4): 50–8PubMedGoogle Scholar
  6. 6.
    Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 2005; 353(9): 898–908PubMedCrossRefGoogle Scholar
  7. 7.
    Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004; 34(5): 881–9PubMedCrossRefGoogle Scholar
  8. 8.
    Atula S, Powles T, Paterson A, et al. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf 2003; 26(9): 661–71PubMedCrossRefGoogle Scholar
  9. 9.
    Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9Suppl. 4: 28–37PubMedCrossRefGoogle Scholar
  10. 10.
    Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002; 77(10): 1044–52PubMedCrossRefGoogle Scholar
  11. 11.
    Ho AY, Kung AW. Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother 2005; 39(9): 1428–33PubMedCrossRefGoogle Scholar
  12. 12.
    Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353(1): 99–102PubMedCrossRefGoogle Scholar
  13. 13.
    Fietta P, Manganelli P, Lodigiani L. Clodronate induced uveitis. Ann Rheum Dis 2003; 62(4): 378PubMedCrossRefGoogle Scholar
  14. 14.
    Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350(12): 1189–99PubMedCrossRefGoogle Scholar
  15. 15.
    Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002; 24(11): 1871–86PubMedCrossRefGoogle Scholar
  16. 16.
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041): 1535–41PubMedCrossRefGoogle Scholar
  17. 17.
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24): 2077–82PubMedCrossRefGoogle Scholar
  18. 18.
    Eisman JA, Rizzoli R, Roman-Ivorra J, et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2004; 20(5): 699–705PubMedCrossRefGoogle Scholar
  19. 19.
    Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004; 19(8): 1259–69PubMedCrossRefGoogle Scholar
  20. 20.
    Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003; 289(19): 2525–33PubMedCrossRefGoogle Scholar
  21. 21.
    Kushida K, Shiraki M, Nakamura T, et al. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab 2004; 22(5): 462–8PubMedCrossRefGoogle Scholar
  22. 22.
    Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9(5): 461–8PubMedCrossRefGoogle Scholar
  23. 23.
    Quandt SA, Thompson DE, Schneider DL, et al. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 2005; 80(3): 343–9PubMedCrossRefGoogle Scholar
  24. 24.
    Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004; 255(4): 503–11PubMedCrossRefGoogle Scholar
  25. 25.
    Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12(1): 1–12Google Scholar
  26. 26.
    Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26(2): 245–56PubMedCrossRefGoogle Scholar
  27. 27.
    Bartl R, Gotte S, Hadji P, et al. Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment [in German]. Dtsch Med Wochenschr 2006; 131(22): 1257–62PubMedCrossRefGoogle Scholar
  28. 28.
    Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161(1): 107–10PubMedCrossRefGoogle Scholar
  29. 29.
    Adami S, Pavelka K, Cline GA, et al. Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80(10): 1278–85PubMedCrossRefGoogle Scholar
  30. 30.
    Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52(11): 1832–9PubMedCrossRefGoogle Scholar
  31. 31.
    Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101(1): 119–23PubMedCrossRefGoogle Scholar
  32. 32.
    Hooper MJ, Ebeling PR, Roberts AP, et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric 2005; 8(3): 251–62PubMedCrossRefGoogle Scholar
  33. 33.
    Leung JY, Ho AY, Ip TP, et al. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. Bone 2005; 36(2): 358–64PubMedCrossRefGoogle Scholar
  34. 34.
    Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20(12): 2105–15PubMedCrossRefGoogle Scholar
  35. 35.
    Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20(1): 141–51PubMedCrossRefGoogle Scholar
  36. 36.
    Drees P, Decking J, Breijawi N, et al. [Osteoporosis and osteoarthritis-is there really an inverse relation?]. Z Orthop Ihre Grenzgeb 2005; 143(2): 161–9PubMedCrossRefGoogle Scholar
  37. 37.
    Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005; 165(3): 346–7PubMedGoogle Scholar
  38. 38.
    Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18(2): 75–85PubMedCrossRefGoogle Scholar
  39. 39.
    Troehler U, Bonjour JP, Fleisch H. Renal secretion of diphosphonates in rats. Kidney Int 1975; 8(1): 6–13PubMedCrossRefGoogle Scholar
  40. 40.
    Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14(9): 1399–405PubMedCrossRefGoogle Scholar
  41. 41.
    Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004; 22(17): 3587–92PubMedCrossRefGoogle Scholar
  42. 42.
    Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111(3): 306–12PubMedCrossRefGoogle Scholar
  43. 43.
    Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241–9CrossRefGoogle Scholar
  44. 44.
    De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer 2005; 13(12): 975–86PubMedCrossRefGoogle Scholar
  45. 45.
    Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15(10): 792–8PubMedCrossRefGoogle Scholar
  46. 46.
    Diel IJ, Body JJ, Lichinitser MR, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004; 40(11): 1704–12PubMedCrossRefGoogle Scholar
  47. 47.
    Felsenberg D, Miller P, Armbrecht G, et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 2005; 37(5): 651–4PubMedCrossRefGoogle Scholar
  48. 48.
    McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004; 19(1): 11–8PubMedCrossRefGoogle Scholar
  49. 49.
    Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20(8): 1315–22PubMedCrossRefGoogle Scholar
  50. 50.
    Tripathy D, Lichinitzer M, Lazarev A, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 2004; 15(5): 743–50PubMedCrossRefGoogle Scholar
  51. 51.
    Reginster JY, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab 2005; 90(9): 5018–24PubMedCrossRefGoogle Scholar
  52. 52.
    Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998; 16(12): 3890–9PubMedGoogle Scholar
  53. 53.
    Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21(5): 389–406PubMedCrossRefGoogle Scholar
  54. 54.
    Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003; 62(10): 969–75PubMedCrossRefGoogle Scholar
  55. 55.
    Thiebaud D, Portmann L, Jaeger P, et al. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy. Bone 1986; 7(4): 247–53PubMedCrossRefGoogle Scholar
  56. 56.
    Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103(4): 298–307PubMedCrossRefGoogle Scholar
  57. 57.
    Jackson GH. Renal safety of ibandronate. Oncologist 2005; 10Suppl. 1: 14–8PubMedCrossRefGoogle Scholar
  58. 58.
    Pecherstorfer M, Diel IJ. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Support Care Cancer 2004; 12(12): 877–81PubMedCrossRefGoogle Scholar
  59. 59.
    Wuster C, Schoter KH, Thiebaud D, et al. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner 1993; 22(2): 77–85PubMedCrossRefGoogle Scholar
  60. 60.
    Heidenreich A. Bisphosphonates in the management of metastatic prostate cancer. Oncology 2003; 65Suppl. 1: 5–11PubMedCrossRefGoogle Scholar
  61. 61.
    Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23(15): 3314–21PubMedCrossRefGoogle Scholar
  62. 62.
    Munier A, Gras V, Andrejak M, et al. Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005; 39(7-8): 1194–7PubMedGoogle Scholar
  63. 63.
    Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005; 66(5): 1054–9PubMedCrossRefGoogle Scholar
  64. 64.
    Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100(1): 36–43PubMedCrossRefGoogle Scholar
  65. 65.
    Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21(16): 3150–7PubMedCrossRefGoogle Scholar
  66. 66.
    Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100(12): 2613–21PubMedCrossRefGoogle Scholar
  67. 67.
    Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 2005; 4(1): 31–7PubMedCrossRefGoogle Scholar
  68. 68.
    Vogel CL, Yanagihara RH, Wood AJ, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 2004; 9(6): 687–95PubMedCrossRefGoogle Scholar
  69. 69.
    Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92(10): 1869–76PubMedCrossRefGoogle Scholar
  70. 70.
    Balla J. The issue of renal safety of zoledronic acid from a nephrologist’s point of view. Oncologist 2005; 10(5): 306–8PubMedCrossRefGoogle Scholar
  71. 71.
    Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 2004; 9(3): 319–29PubMedCrossRefGoogle Scholar
  72. 72.
    Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18(6): 1378–91PubMedGoogle Scholar
  73. 73.
    Lugassy G. “Safety and convenience of a 15-minute infusion of zoledronic acid”: not so safe. Oncologist 2005; 10(5): 309–10PubMedCrossRefGoogle Scholar
  74. 74.
    van Beek ER, Cohen LH, Leroy IM, et al. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003; 33(5): 805–11PubMedCrossRefGoogle Scholar
  75. 75.
    Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 2003; 25(11): 2669–708PubMedCrossRefGoogle Scholar
  76. 76.
    Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359(9321): 1929–36PubMedCrossRefGoogle Scholar
  77. 77.
    Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004; 62(3): 391–2PubMedCrossRefGoogle Scholar
  78. 78.
    Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353(1): 99–102PubMedCrossRefGoogle Scholar
  79. 79.
    Wooltorton E. Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ 2005; 172(13): 1684PubMedCrossRefGoogle Scholar
  80. 80.
    Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62(5): 527–34PubMedCrossRefGoogle Scholar
  81. 81.
    Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34): 8580–7PubMedCrossRefGoogle Scholar
  82. 82.
    Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302(3): 1055–61PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Raja S Bobba
    • 1
  • Karen Beattie
    • 1
  • Bill Parkinson
    • 2
  • Dinesh Kumbhare
    • 3
  • Jonathan D. Adachi
    • 1
  1. 1.Division of RheumatologyMcMaster UniversityHamiltonCanada
  2. 2.School of Rehabilitation Science, McMaster UniversityHamiltonCanada
  3. 3.Department of MedicineMcMaster UniversityHamiltonCanada

Personalised recommendations